Label (71610 0796 30)
Rosuvastatin Tablet, Film Coated
Product Images NDC 71610-796
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 71610-796). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena (Aphena)
Figure-01 (Figure 1)
Figure-02 (Figure 2)
This text provides data on the comparison of the effects of Rosuvastatin 20 mg versus Placebo 20 mg on various endpoints in a study with 8901 participants. The results include hazard ratios with confidence intervals and p-values for different events such as major cardiovascular events, cardiovascular death, nonfatal stroke, nonfatal MI (myocardial infarction), and unstable angina. The outcomes suggest significant differences favoring Rosuvastatin over Placebo in reducing the risk of these adverse events. It also mentions the inclusion criteria for cardiovascular death.*
Figure-02 (Figure 3)
Structural Formula (Rosuvastatin Str)
Not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
